Jerry Avorn

52.3k total citations · 15 hit papers
517 papers, 38.6k citations indexed

About

Jerry Avorn is a scholar working on Economics and Econometrics, Pharmacology and Geriatrics and Gerontology. According to data from OpenAlex, Jerry Avorn has authored 517 papers receiving a total of 38.6k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Economics and Econometrics, 86 papers in Pharmacology and 76 papers in Geriatrics and Gerontology. Recurrent topics in Jerry Avorn's work include Health Systems, Economic Evaluations, Quality of Life (165 papers), Pharmaceutical Economics and Policy (140 papers) and Pharmaceutical industry and healthcare (78 papers). Jerry Avorn is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (165 papers), Pharmaceutical Economics and Policy (140 papers) and Pharmaceutical industry and healthcare (78 papers). Jerry Avorn collaborates with scholars based in United States, New Zealand and Canada. Jerry Avorn's co-authors include Sebastian Schneeweiß, Robert J. Glynn, Aaron S. Kesselheim, Stephen B. Soumerai, Daniel H. Solomon, Raisa Levin, Helen Mogun, Philip S. Wang, Til Stürmer‎ and William H. Shrank and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Jerry Avorn

513 papers receiving 36.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Variable Selection for Propensity Score Models

2006 1.6k citations M. Alan Brookhart, Sebastian Schneeweiß et al. profile →
A review of uses of health care utilization databases for epidemiologic research on therapeutics

2005 995 citations Sebastian Schneeweiß, Jerry Avorn profile →
High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

2009 845 citations Sebastian Schneeweiß, Robert J. Glynn et al. profile →
A combined comorbidity score predicted mortality in elderly patients better than existing scores

2011 768 citations Robert J. Glynn, Jerry Avorn et al. profile →
Improving Drug-Therapy Decisions through Educational Outreach

1983 697 citations Jerry Avorn et al. New England Journal of Medicine profile →
Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications

2005 684 citations Philip S. Wang, Sebastian Schneeweiß et al. New England Journal of Medicine profile →
Self-management Education Programs in Chronic Disease

2004 562 citations Philip S. Wang, Jerry Avorn et al. profile →
Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer

2003 553 citations Philip S. Wang, Jerry Avorn et al. profile →
Persistence of Use of Lipid-Lowering Medications

1998 548 citations Jerry Avorn, Johanne Monette et al. profile →
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods

2005 524 citations Til Stürmer‎, Robert J. Glynn et al. profile →
Full Coverage for Preventive Medications after Myocardial Infarction

2011 508 citations Niteesh K. Choudhry, Jerry Avorn et al. New England Journal of Medicine profile →
Scientific versus commercial sources of influence on the prescribing behavior of physicians

1982 442 citations Jerry Avorn et al. profile →
Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index

2017 426 citations Dae Hyun Kim, Sebastian Schneeweiß et al. The Journals of Gerontology Series A profile →
The High Cost of Prescription Drugs in the United States

2016 394 citations Aaron S. Kesselheim, Jerry Avorn et al. profile →
FDA Approval and Regulation of Pharmaceuticals, 1983-2018

2020 220 citations Jerry Avorn, Aaron S. Kesselheim et al. profile →

Peers

Countries citing papers authored by Jerry Avorn

Since Specialization

Citations

This map shows the geographic impact of Jerry Avorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Avorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Avorn more than expected).

Fields of papers citing papers by Jerry Avorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Avorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Avorn. The network helps show where Jerry Avorn may publish in the future.

Co-authorship network of co-authors of Jerry Avorn

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Avorn. A scholar is included among the top collaborators of Jerry Avorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Avorn. Jerry Avorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient Characteristics Associated With Using Transcatheter Left Atrial Appendage Occlusion Versus Oral Anticoagulants for Atrial Fibrillation 2024 ·Circulation Cardiovascular Quality and Outcomes ·Kueiyu Joshua Lin, Daniel E. Singer, Jerry Avorn, E. Kevin Heist, Sushama Kattinakere Sreedhara, (unknown), Yichi Zhang, (unknown), Sebastian Schneeweiß	3
2	Overcoming Decisional Gaps in High-Risk Prescribing by Junior Physicians Using Simulation-Based Training: Protocol for a Randomized Controlled Trial 2022 ·JMIR Research Protocols ·Julie C. Lauffenburger, (unknown), (unknown), (unknown), Erin Kim, Maxwell Coll, Nancy Haff, Constance P. Fontanet, (unknown), (unknown), Jerry Avorn, Niteesh K. Choudhry	2
3	Prescribing decision making by medical residents on night shifts: A qualitative study 2022 ·Medical Education ·Julie C. Lauffenburger, Maxwell Coll, Erin Kim, (unknown), (unknown), Nancy Haff, (unknown), Jerry Avorn, Niteesh K. Choudhry	7
4	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis 2018 ·JMIR Public Health and Surveillance ·Michael S. Sinha, Clark C. Freifeld, John S. Brownstein, Macarius Donneyong, (unknown), (unknown), Esther H. Zhou, Gerald J. Dal Pan, Ajinkya Pawar, Thomas J. Hwang, Jerry Avorn, Aaron S. Kesselheim	20
5	Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov 2018 ·BMJ Open ·Laura E. Bothwell, Jerry Avorn, Nazleen F. Khan, Aaron S. Kesselheim	95
6	Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index breakdown → 2017 ·The Journals of Gerontology Series A ·Dae Hyun Kim, Sebastian Schneeweiß, Robert J. Glynn, Lewis A. Lipsitz, Kenneth Rockwood, Jerry Avorn	426
7	Medication adherence and healthcare disparities: impact of statin co-payment reduction. 2015 ·PubMed ·Jennifer Lewey, William H. Shrank, Jerry Avorn, Jun Liu, Niteesh K. Choudhry	28
8	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration 2011 ·Pharmacoepidemiology and Drug Safety ·Amanda R. Patrick, Sebastian Schneeweiß, M. Alan Brookhart, Robert J. Glynn, Kenneth J. Rothman, Jerry Avorn, Til Stürmer‎	102
9	Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. 2010 ·PubMed ·Philip S. Wang, Amanda R. Patrick, Colin R. Dormuth, Malcolm Maclure, Jerry Avorn, Claire Canning, Sebastian Schneeweiß	11
10	Using Patent Data to Assess the Value of Pharmaceutical Innovation 2009 ·SSRN Electronic Journal ·Aaron S. Kesselheim, Jerry Avorn	1
11	Drug Review Deadlines and Subsequent Safety Problems 2008 ·New England Journal of Medicine ·Daniel Carpenter, Evan J. Zucker, Jerry Avorn	1
12	Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups 2008 ·Arthritis Care & Research ·Daniel H. Solomon, Robert J. Glynn, Kenneth J. Rothman, Sebastian Schneeweiß, Soko Setoguchi, Helen Mogun, Jerry Avorn, Til Stürmer‎	78
13	Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use 2007 ·Journal of General Internal Medicine ·William H. Shrank, Margaret Stedman, Susan L. Ettner, (unknown), (unknown), M. Alan Brookhart, Michael A. Fischer, Jerry Avorn, Steven M. Asch	54
14	Assessment of education and computerized decision support interventions for improving transfusion practice 2006 ·Transfusion ·Jeffrey M. Rothschild, Siobhan McGurk, Melissa Honour, (unknown), (unknown), (unknown), W. Hallowell Churchill, Richard M. Kaufman, Jerry Avorn, E. Francis Cook, David W. Bates	98
15	Extensions of Intellectual Property Rights and Delayed Adoption of Generic Drugs: Effects on Medicaid Expenditures 2006 ·SSRN Electronic Journal ·Aaron S. Kesselheim, Jerry Avorn, Michael A. Fischer	1
16	Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction 2004 ·The American Journal of Cardiology ·Jerry Avorn, Eric L. Knight, David A. Ganz, Sebastian Schneeweiß	16
17	Patterns of Bone Mineral Density Testing 2004 ·Journal of General Internal Medicine ·Charles A. Morris, Danielle Cabral, (unknown), Jeffrey N. Katz, Joel S. Finkelstein, Jerry Avorn, Daniel H. Solomon	62
18	COX‐2 selective non‐steroidal anti‐inflammatory drugs and cardiovascular disease 2002 ·Pharmacoepidemiology and Drug Safety ·Wayne A. Ray, Thomas M. MacDonald, Daniel H. Solomon, David J. Graham, Jerry Avorn	17
19	Concurrent Use of Antiulcerative Agents 1997 ·Journal of Clinical Gastroenterology ·Johanne Monette, Helen Mogun, Rhonda L. Bohn, Jerry Avorn	2
20	Ethics and experts. 2. A physician's perspective. 1982 ·PubMed ·Jerry Avorn	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact